Pfizer 3Q Revenues: $13.0 billion (+8%) 3Q Earnings: $1.3 billion (-38%) YTD Revenues: $39.2 billion (+13%) YTD Earnings: $6.4 billion (-11%) Comments: Pfizer Innovative Health revenues (formerly the Innovative Products business) were $7.3 billion in the quarter, up 9% driven by growth from key brands including Ibrance, primarily in the U.S., Eliquis globally, as well as Xeljanz, Lyrica and Chantix/Champix,primarily in the U.S.  Ibrance sales were $550 million in the quarter. Eliq...